T-cell homeostasis in chronic HCV-infected patients treated with interferon and ribavirin or an interferon-free regimen
Hans Jakob Hartling
Viro-Immunology Research Unit, Department of Infectious Diseases, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Department of Clinical Immunology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Search for more papers by this authorCarsten Birch
Viro-Immunology Research Unit, Department of Infectious Diseases, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Department of Clinical Immunology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Search for more papers by this authorJulie C. Gaardbo
Viro-Immunology Research Unit, Department of Infectious Diseases, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Department of Clinical Immunology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Search for more papers by this authorMalene Hove
Viro-Immunology Research Unit, Department of Infectious Diseases, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Department of Clinical Immunology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Search for more papers by this authorMarius Trøseid
Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway
Search for more papers by this authorMette Rye Clausen
Department of Hepatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Search for more papers by this authorJan Gerstoft
Viro-Immunology Research Unit, Department of Infectious Diseases, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Search for more papers by this authorHenrik Ullum
Department of Clinical Immunology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Search for more papers by this authorCorresponding Author
Susanne Dam Nielsen
Viro-Immunology Research Unit, Department of Infectious Diseases, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Susanne Dam Nielsen, Viro-immunology Research Unit, Department of Infectious Diseases, University Hospital of Copenhagen, Blegdamsvej 9b, 2100 Copenhagen, Denmark. e-mail: [email protected]Search for more papers by this authorHans Jakob Hartling
Viro-Immunology Research Unit, Department of Infectious Diseases, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Department of Clinical Immunology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Search for more papers by this authorCarsten Birch
Viro-Immunology Research Unit, Department of Infectious Diseases, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Department of Clinical Immunology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Search for more papers by this authorJulie C. Gaardbo
Viro-Immunology Research Unit, Department of Infectious Diseases, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Department of Clinical Immunology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Search for more papers by this authorMalene Hove
Viro-Immunology Research Unit, Department of Infectious Diseases, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Department of Clinical Immunology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Search for more papers by this authorMarius Trøseid
Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway
Search for more papers by this authorMette Rye Clausen
Department of Hepatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Search for more papers by this authorJan Gerstoft
Viro-Immunology Research Unit, Department of Infectious Diseases, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Search for more papers by this authorHenrik Ullum
Department of Clinical Immunology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Search for more papers by this authorCorresponding Author
Susanne Dam Nielsen
Viro-Immunology Research Unit, Department of Infectious Diseases, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Susanne Dam Nielsen, Viro-immunology Research Unit, Department of Infectious Diseases, University Hospital of Copenhagen, Blegdamsvej 9b, 2100 Copenhagen, Denmark. e-mail: [email protected]Search for more papers by this authorAbstract
Direct-acting antiviral has replaced pegylated interferon-α and ribavirin-based treatment in the treatment of chronic hepatitis C virus (HCV) infection. While interferon-α is immune modulating and causes lymphopenia, interferon-free regimens seem to be well-tolerated. This study aimed to compare T-cell homeostasis before, during, and after HCV treatment with or without interferon-α in patients with chronic HCV infection. A total of 20 patients with chronic HCV infection were treated with pegylated interferon-α and ribavirin, and six patients were treated with an interferon-free regimen. All patients were treated for a minimum of 12 weeks. Interferon-α treatment caused an increase in the density of the receptor for IL-7 (IL-7Rα) during treatment, while interferon-free regimens caused a decrease in IL-7Rα density. After a sustained viral response, proportions of IL-7Rα+ T cells and IL-7Rα density decreased compared to prior treatment values. Finally, a proportion of CD8+ effector memory was lower while proportion of apoptotic T cells was higher after sustained virologic response compared to prior treatment. Despite lymphopenia during interferon, alterations in T-cell homeostasis during treatment were relatively similar in patients receiving interferon-based treatment and in patients receiving interferon-free treatment, and alterations during and after treatment seem to illustrate a reduced need for high levels of T cells aimed at controlling infection.
References
- 1Asselah T, Marcellin P. New direct-acting antivirals' combination for the treatment of chronic hepatitis C. Liver Int 2011; 31(Suppl 1): 68–77.
- 2Chander G, Sulkowski MS, Jenckes MW, Torbenson MS, Herlong HF, Bass EB, et al. Treatment of chronic hepatitis C: a systematic review. Hepatology 2002; 36: S135–44.
- 3Arizcorreta A, Márquez M, Fernández-Gutiérrez C, Guzmán EP, Brun F, Rodríguez-Iglesias M, et al. T cell receptor excision circles (TRECs), CD4+, CD8+, and their CD45RO+, and CD45RA+, subpopulations in hepatitis C virus (HCV)-HIV-co-infected patients during treatment with interferon alpha plus ribavirin: analysis in a population on effective antiretroviral therapy. Clin Exp Immunol 2006; 146: 270–7.
- 4Landau A, Batisse D, Duong Van Huyen JP, Piketty C, Bloch F, Pialoux G, et al. Efficacy and safety of combination therapy with interferon-alpha2b and ribavirin for chronic hepatitis C in HIV-infected patients. AIDS 2000; 14: 839–44.
- 5Lin Q, Dong C, Cooper MD. Impairment of T and B cell development by treatment with a type I interferon. J Exp Med 1998; 187: 79–87.
- 6Nelson DR, Zeuzem S, Andreone P, Ferenci P, Herring R, Jensen DM, et al. Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients. Ann Hepatol 2012; 11: 15–31.
- 7Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417–28.
- 8Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncalec FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–82.
- 9Feeney ER, Chung RT. Antiviral treatment of hepatitis C. BMJ 2014; 348: g3308.
- 10Pillai V, Lee WM, Thiele DL, Karandikar NJ. Clinical responders to antiviral therapy of chronic HCV infection show elevated antiviral CD4+ and CD8+ T-cell responses. J Viral Hepat 2007; 14: 318–29.
- 11Pilli M, Zerbini A, Penna A, Orlandini A, Lukasiewicz E, Pawlotsky J-M, et al. HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project). Gastroenterology 2007; 133: 1132–43.
- 12Lee S, Hammond T, Watson MW, Flexman JP, Cheng W, Fernandez S, et al. Could a loss of memory T cells limit responses to hepatitis C virus (HCV) antigens in blood leucocytes from patients chronically infected with HCV before and during pegylated interferon-alpha and ribavirin therapy? Clin Exp Immunol 2010; 161: 118–26.
- 13Caetano J, Martinho A, Paiva A, Pais B, Valente C, Luxo C. Differences in hepatitis C virus (HCV)-specific CD8 T-cell phenotype during pegylated alpha interferon and ribavirin treatment are related to response to antiviral therapy in patients chronically infected with HCV. J Virol 2008; 82: 7567–77.
- 14Neau-Cransac M, Foucher J, De Ledinghen V, Bernard P-H, Legrand E, Lafon M-E. Modifications of T-lymphocyte subsets before and during interferon and ribavirin treatment for chronic hepatitis C infection. Viral Immunol 2005; 18: 197–204.
- 15Clausen LN, Lundbo LF, Benfield T. Hepatitis C virus infection in the human immunodeficiency virus infected patient. World J Gastroenterol 2014; 20: 12132–43.
- 16Hartling HJ, Gaardbo JC, Ronit A, Salem M, Laye M, Clausen MR, et al. Impaired thymic output in patients with chronic hepatitis C virus infection. Scand J Immunol 2013; 78: 378–86.
- 17Gaardbo JC, Hartling HJ, Ronit A, Thorsteinsson K, Madsen HO, Springborg K, et al. Different immunological phenotypes associated with preserved CD4+ T cell counts in HIV-infected controllers and viremic long term non-progressors. PLoS ONE 2013; 8: e63744.
- 18Pedersen KK, Pedersen M, Trøseid M, Gaardbo JC, Lund TT, Thomsen C, et al. Microbial translocation in HIV infection is associated with dyslipidemia, insulin resistance, and risk of myocardial infarction. J Acquir Immune Defic Syndr 2013; 64: 425–33.
- 19Sulkowski M, Hezode C, Gerstoft J, Vierling JM, Mallolas J, Pol S, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2014; 6736: 1–11.
- 20Chung RT, Gale M, Polyak SJ, Lemon SM, Liang TJ, Hoofnagle JH. Mechanisms of action of interferon and ribavirin in chronic hepatitis C: summary of a workshop. Hepatology 2008; 47: 306–20.
- 21Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005; 436: 967–72.
- 22McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580–93.
- 23Beq S, Rozlan S, Pelletier S, Willems B, Bruneau J, Lelievre J-D, et al. Altered thymic function during interferon therapy in HCV-infected patients. PLoS ONE 2012; 7: e34326.
- 24Massanella M, Tural C, Papagno L, Garcia E, Jou A, Bofill M, et al. Changes in T-cell subsets in HIV-HCV-coinfected patients during pegylated interferon-alpha2a plus ribavirin treatment. Antivir Ther 2010; 15: 333–42.
- 25Kared H, Saeed S, Klein MB, Shoukry NH. CD127 expression, exhaustion status and antigen specific proliferation predict sustained virologic response to IFN in HCV/HIV co-infected individuals. PLoS ONE 2014; 9: e101441.
- 26Gonzalez VD, Falconer K, Blom KG, Reichard O, Mørn B, Laursen AL, et al. High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment. J Virol 2009; 83: 11407–11.
- 27Sprent J, Surh CD. Normal T cell homeostasis: the conversion of naive cells into memory-phenotype cells. Nat Immunol 2011; 131: 478–84.
- 28Marchetti G, Nasta P, Bai F, Gatti F, Bellistrì GM, Tincati C, et al. Circulating sCD14 is associated with virological response to pegylated-interferon-alpha/ribavirin treatment in HIV/HCV co-infected patients. PLoS ONE 2012; 7: e32028.
